Cocrystal Pharma, Inc. 8-K

What Happened

• On April 2, 2026, Cocrystal Pharma, Inc. (NASDAQ: COCP) announced via press release (filed on Form 8-K, Item 7.01) that the U.S. Food and Drug Administration granted Fast Track designation to CDI-988, the company’s oral, direct-acting protease inhibitor being developed as the first oral antiviral candidate for treatment and prophylaxis of norovirus infection.

Key Details

• Date: April 2, 2026 (press release furnished as Exhibit 99.1 in the Form 8-K).
• Drug: CDI-988 — described as an oral, direct-acting protease inhibitor.
• Indication: Treatment and prophylaxis of norovirus infection; noted as the company’s first oral antiviral candidate for this purpose.
• Filing: Disclosure made under Item 7.01 (Regulation FD Disclosure) of Form 8-K; Exhibit 99.1 included.

Why It Matters

• Fast Track designation is intended to facilitate the development and expedite review of drugs for serious conditions; for investors, this can mean more frequent interactions with the FDA and the potential for accelerated regulatory pathways. It is a regulatory milestone that may increase the program’s visibility, but it does not guarantee approval or a specific timeline.